Gilead Sciences’s new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.
from WSJ.com: What’s News US http://ift.tt/1tBxeDe
via IFTTT
For everything from family to computers…
Gilead Sciences’s new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.
from WSJ.com: What’s News US http://ift.tt/1tBxeDe
via IFTTT